Acro Biomedical (ACBM) EV to FCF (2018 - 2025)

Acro Biomedical has reported EV to FCF for 8 years, with the latest figure at 47.16 in Q4 2025.

• On a quarterly basis, EV to FCF changed N/A year-over-year to 47.16 in Q4 2025; TTM through Dec 2025 was 6.1, a N/A change from a year earlier, with the FY2025 full-year figure at 4.85, changed N/A from the prior year.
• EV to FCF was 47.16 for Q4 2025 at Acro Biomedical, up from 948.53 in the prior quarter.
• The five-year high for EV to FCF was 186450.31 in Q3 2023, with the low at 45845.12 in Q1 2023.
• Average EV to FCF over 5 years is 7623.66, with a median of 737.95 recorded in 2022.
• The largest YoY upside for EV to FCF was 4258.14% in 2023 against a maximum downside of 5111.24% in 2023.
• Over 5 years, EV to FCF stood at 4612.77 in 2021, then tumbled by 454.25% to 25566.16 in 2022, then jumped by 98.14% to 476.0 in 2023, then plunged by 99.27% to 948.53 in 2024, then surged by 95.03% to 47.16 in 2025.
• The last three EV to FCF figures came in at 47.16 (Q4 2025), 948.53 (Q2 2024), and 444.32 (Q1 2024), per Business Quant data.